FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer
Status:
Recruiting
Trial end date:
2022-08-02
Target enrollment:
Participant gender:
Summary
The main cause of recurrence after surgical treatment of colorectal cancer is distant
metastasis. Neoadjuvant chemotherapy has potential benefits of improving the effectiveness of
chemotherapy. Preoperative chemotherapy may eradicate microscopic metastatic cancer cells
earlier than adjuvant chemotherapy, reduce cancer cell spillage during surgery, and lessen
the invasiveness of surgical resection. The FOLFOXIRI regimen has been shown to have a high
objective efficiency in advanced colorectal cancer. This phase II trial is to explore the
pathological remission rate and safety of stage II/III locally advanced colon cancer with
high risk of recurrence to FOLFOXIRI regimen of neoadjuvant chemotherapy alone.